Home » Stocks » Nurix Therapeutics

Nurix Therapeutics, Inc. (NRIX)

Stock Price: $18.23 USD 0.61 (3.46%)
Updated Aug 7, 2020 4:00 PM EDT - Market closed
After-hours: $17.00 -1.23 (-6.75%) Aug 7, 4:15 PM

Stock Price Chart

Key Info

Market Cap 675.20M
Revenue (ttm) 19.49M
Net Income (ttm) n/a
Shares Out 34.84M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 7, 2020
Last Price $18.23
Previous Close $17.62
Change ($) 0.61
Change (%) 3.46%
Day's Open 17.76
Day's Range 17.51 - 18.45
Day's Volume 672,354
52-Week Range 16.63 - 22.47

More Stats

Market Cap 675.20M
Enterprise Value 501.53M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 34.84M
Float 1.93M
EPS (basic) n/a
EPS (diluted) n/a
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short n/a
Short Ratio n/a
Short % of Float n/a
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 34.65
PB Ratio 6.80
Revenue 19.49M
Operating Income n/a
Net Income n/a
Free Cash Flow n/a
Net Cash 173.67M
Net Cash / Share 4.69
Gross Margin -71.38%
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA n/a
ROE n/a
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

*No analysts have provided price targets for this stock.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-53.35-47.19
Net Income-21.70-9.43
Shares Outstanding3.292.82
Earnings Per Share-6.59-3.35
Cash & Equivalents37.8939.21
Net Cash / Debt37.8939.21
Book Value-57.71-36.85
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Nurix Therapeutics, Inc.
Country United States
Employees 103
CEO Arthur T. Sands

Stock Information

Ticker Symbol NRIX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: NRIX
IPO Date July 24, 2020


Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company's lead product candidates in preclinical stage include NX-2127, an orally available Bruton's tyrosine kinase degrader for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B inhibitor for immuno-oncology indications. It also provides DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a class of enzymes that could modulate proteins within the cell. Nurix Therapeutics, Inc. has a strategic collaboration agreement with Gilead Sciences, Inc.; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was founded in 2009 and is headquartered in San Francisco, California.